Item 2.02      Results of Operations and Financial Condition.
On August 16, 2021, Sema4 Holdings Corp. ("Sema4 Holdings" or the "Company")
issued a press release (the "Press Release") and will hold a conference call
announcing the financial results of Mount Sinai Genomics, Inc. dba Sema4
("Sema4"), which the Company combined with in its previously announced business
combination transaction, for the three and six months ended June 30, 2021.
Copies of the Press Release and Earnings Presentation are furnished as Exhibits
99.1 and 99.2, respectively, to this Current Report on Form 8-K.
The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2,
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference into any other filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item 4.01      Changes in Registrant's Certifying Accountant
(b) Newly Appointed Independent Registered Public Accountant
On August 13, 2021, the Audit Committee of the Company's Board of Directors
approved the appointment of Ernst & Young LLP ("EY") as the Company's new
independent registered public accounting firm to audit the Company's
consolidated financial statements for the year ended December 31, 2021.
During the year period from July 10, 2020 (inception) to December 31, 2020, and
the interim periods through June 30, 2021, the Company did not consult EY with
respect to either (i) the application of accounting principles to a specified
transaction, either completed or proposed; or the type of audit opinion that
might be rendered on the Company's financial statements, and no written report
or oral advice was provided to the Company by EY that EY concluded was an
important factor considered by the Company in reaching a decision as to the
accounting, auditing or financial reporting issue; or (ii) any matter that was
either the subject of a disagreement, as that term is described in Item
304(a)(1)(iv) of Regulation S-K under the Exchange Act and the related
instructions to Item 304 of Regulation S-K under the Exchange Act, or a
reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K
under the Exchange Act.
Item 9.01.      Financial Statement and Exhibits.
(d) Exhibits.
     Exhibit
     Number                                           Description
      99.1          Press Release, dated August 16, 2021, regarding the Registrant's results for the
                  quarter ended June 30, 2021
      99.2               E    arnings Presentation    , dated August 16, 2021


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses